Transactions
11
Insider / Arcutis Biotherapeutics, Inc.
Curran Terrie
Director at Arcutis Biotherapeutics, Inc.
Curran Terrie, Director at Arcutis Biotherapeutics, Inc., has disclosed 11 transactions in ARQT since June 9, 2026: 0 purchases (0 open-market buys) and 3 sales, worth about $1.3M at the reported prices. The latest was filed August 28, 2026, 1 day after the trade.
Open-market buys
0
Sales
3
Avg. disclosure lag
2.4d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Curran Terrie made no purchases and 3 sales worth $984K, plus 8 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Curran Terrie has traded 1 stock on record; the largest by dollars is ARQT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 6 | 78,544 | $325K |
| S | Open-market sale | 3 | 39,272 | $984K |
| A | Grant or award | 2 | 22,445 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 11 | 0 | 3 · $984K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ARQT | Option / conversion M | August 27, 2026 | August 28, 2026 | 1d | 27,052 | — | — | derivative | Form 4 ↗ | |
| ARQT | Option / conversion M | August 27, 2026 | August 28, 2026 | 1d | 11,148 | — | — | derivative | Form 4 ↗ | |
| ARQT | Sell S | August 27, 2026 | August 28, 2026 | 1d | 27,052 | $25 | $677K | Form 4 ↗ | ||
| ARQT | Option / conversion M | August 27, 2026 | August 28, 2026 | 1d | 27,052 | $9 | $233K | Form 4 ↗ | ||
| ARQT | Sell S | August 27, 2026 | August 28, 2026 | 1d | 11,148 | $25 | $279K | Form 4 ↗ | ||
| ARQT | Option / conversion M | August 27, 2026 | August 28, 2026 | 1d | 11,148 | $8 | $84K | Form 4 ↗ | ||
| ARQT | Option / conversion M | August 20, 2026 | August 24, 2026 | 4d | 1,072 | — | — | derivative | Form 4 ↗ | |
| ARQT | Sell S | August 20, 2026 | August 24, 2026 | 4d | 1,072 | $26 | $28K | Form 4 ↗ | ||
| ARQT | Option / conversion M | August 20, 2026 | August 24, 2026 | 4d | 1,072 | $8 | $8,051 | Form 4 ↗ | ||
| ARQT | Other A | June 5, 2026 | June 9, 2026 | 4d | 16,667 | — | — | derivative | Form 4 ↗ | |
| ARQT | Other A | June 5, 2026 | June 9, 2026 | 4d | 5,778 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 28, 2026 | Form 4 | 0001628280-26-059444 | 6 | published | EDGAR ↗ |
| August 24, 2026 | Form 4 | 0001628280-26-058648 | 3 | published | EDGAR ↗ |
| June 9, 2026 | Form 4 | 0001628280-26-042042 | 2 | published | EDGAR ↗ |
Other insiders at Arcutis Biotherapeutics, Inc.
- Welgus Howard G. Director 49 rows
- Burnett Patrick See Remarks 29 rows
- Matsuda Masaru See Remarks 20 rows
- Watanabe Todd See Remarks 15 rows
- Leonard Keith R Director 13 rows
- Edwards Larry Todd See Remarks 8 rows
- Krishnamohan Neha Director 8 rows
- LIN SUE-JEAN Director 8 rows
- Vairavan Latha SVP Chief Financial Officer 8 rows
- Gilbert Halley E Director 7 rows
Everyone on file, with contracts and lobbying under the company's name: Arcutis Biotherapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 11 | June 9, 2026 | August 28, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.